Abstract
It is well documented that immunotherapy has a great potential for cancer treatment. The ideal cancer immunotherapeutic strategies should be relatively simple, but able to trick the host’s immune system to elicit a robust immune response to the tumor target. Herpes Simplex Virus (HSV) has been engineered for the purpose of oncolysis. These so-called oncolytic HSVs can selectively replicate within tumor cells, resulting in their destruction and in the production of progeny virions that can spread to adjacent tumor cells. In addition to their direct oncolytic effect, tumor lysis by oncolytic viruses releases tumor antigens in their native form and configuration in an individualized way. Immune responses thus generated would be more likely to recognize the original tumor than would tumor vaccines produced by other methods, most of which require extensive in vitro modification and manipulation. Several recently published studies have shown that HSV-elicited antitumor immune responses are an essential part of the overall antitumor effect produced by oncolytic HSVs, not only for controlling primary tumor growth, but also for preventing long distance metastases. In this chapter several key methods will be illustrated to monitor the immune response elicited by oncolytic HSVs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weiner, L. M. (2008) Cancer immunotherapy – the endgame begins. N Engl J Med 358, 2664–2665.
Waldmann, T. A. (2003) Immunotherapy: past, present and future. Nat Med 9, 269–277.
Russell, S. J., and Peng, K. W. (2007) Viruses as anticancer drugs. Trends Pharmacol Sci 28, 326–333.
Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P., Parish, I. A., Davey, G. M., Wilson, N. S., Carbone, F. R., and Villadangos, J. A. (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199, 9–26.
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S., and Zitvogel, L. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7, 297–303.
Todo, T. (2008) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 13, 2060–2064.
Varghese, S., and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9, 967–978.
Randazzo, B. P., Kesari, S., Gesser, R. M., Alsop, D., Ford, J. C., Brown, S. M., Maclean, A., and Fraser, N. W. (1995) Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94–101.
Wong, R. J., Kim, S. H., Joe, J. K., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193, 12–21.
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938–943.
Wong, R. J., Patel, S. G., Kim, S., DeMatteo, R. P., Malhotra, S., Bennett, J. J., St-Louis, M., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12, 253–265.
Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006) Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12, 643–652.
Li, H., Zeng, Z., Fu, X., and Zhang, X. (2007) Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res 67, 7850–7855.
Li, H., Dutuor, A., Fu, X., and Zhang, X. (2007) Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 9, 161–169.
Li, H., Dutuor, A., Tao, L., Fu, X., and Zhang, X. (2007) Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13, 316–322.
Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M. K., and Zhang, X. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 7, 748–754.
Fu, X., Tao, L., Cai, R., Prigge, J., and Zhang, X. (2006) A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 13, 882–890.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Li, H., Zhang, X. (2010). Oncolytic HSV as a Vector in Cancer Immunotherapy. In: Yotnda, P. (eds) Immunotherapy of Cancer. Methods in Molecular Biology, vol 651. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-786-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-60761-786-0_16
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-785-3
Online ISBN: 978-1-60761-786-0
eBook Packages: Springer Protocols